https://www.selleckchem.com/products/mln2480.html
30, p less then 0.001), mood (B = 1.31, Wald χ21 = 40.38, OR = 3.70, p less then 0.001), and anxiety (B = 1.72, Wald χ21 = 45.28, OR = 5.60, p less then 0.001) disorders were also associated with megestrol use. CONCLUSIONS Patients taking megestrol were significantly more likely to develop a new psychiatric diagnosis than comparison patients. Highest risks were associated with the development of cognitive diagnoses. The findings suggest that megestrol, like other glucocorticoid agonists, is associated with an increased risk of developin
Like
Comment
Share
